StartsideJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
140,22 $
Etterbørs:(0,00 %)0,00
140,22 $
Stengt: 3. mars, 17:20:00 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Forrige sluttkurs
143,53 $
Dagsintervall
139,60 $ - 145,40 $
Årsintervall
99,06 $ - 148,06 $
Markedsverdi
8,48 mrd. USD
Gjennomsnittlig volum
788,34k
P/E-tall
16,21
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | des. 2024info | Endring år til år |
|---|---|---|
Omsetning | 1,09 mrd. | 7,53 % |
Driftskostnader | 768,69 mill. | 9,42 % |
Nettoomsetning | 191,12 mill. | 102,98 % |
Netto resultatmargin | 17,56 | 88,82 % |
Fortjeneste per aksje | 6,60 | 31,47 % |
EBITDA | 396,98 mill. | 0,82 % |
Faktisk avgiftssats | −43,48 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | des. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 2,99 mrd. | 83,66 % |
Totale aktiva | 12,01 mrd. | 5,43 % |
Totale passiva | 7,92 mrd. | 3,42 % |
Total egenkapital | 4,09 mrd. | — |
Utestående aksjer | 60,73 mill. | — |
P/B-forhold | 2,13 | — |
Avkastning på aktiva | 4,71 % | — |
Avkastning på kapital | 5,54 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | des. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | 191,12 mill. | 102,98 % |
Kontantstrøm fra drift | 398,58 mill. | 138,19 % |
Kontanter fra investering | −193,29 mill. | −289,87 % |
Kontanter fra finansiering | −8,28 mill. | 91,75 % |
Netto kontantstrøm | 194,73 mill. | 14,13 % |
Fri kontantstrøm | 466,32 mill. | 470,30 % |
Om
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Administrerende direktør
Grunnlagt
2003
Nettsted
Ansatte
2 800
